However, despite new technologies and therapies that target hyperglycemia, such as new oral agents (including GLP-1 analogs), new insulin and continuous glucose monitors (CGM), hypoglycemia remains a major barrier to tight glycemic control, even in patients with type 2 diabetes (T2D) (Balijepalli et al., 2017; Goyal et al., 2017; Hædersdal et al., 2018). This evidence concerns the gene INS and Hypoglycemia.